COVID-19疫苗接种前住院后的医疗费用变化
该研究基于Merative MarketScan数据库,采用倾向性评分匹配比较商业保险中因COVID-19住院患者(病例组)与未住院COVID-19患者(对照组)的医疗支出趋势,发现住院患者初始就诊后30天总医疗支出平均高96%,120天高近70%,且在高血压或糖尿病患者中差异更大。
要点
- COVID-19住院患者30天后总医疗支出平均高96%,120天后高近70%。
- 30天后平均支出差异为11242美元,120天后为4959美元。
- 合并高血压或糖尿病者支出差异更大,30天后为14958美元,120天后为5962美元。
核心结论
- COVID-19住院与后续医疗费用增加相关,支持接种疫苗以减轻健康和经济影响。
研究设计与样本
- 使用Merative MarketScan数据库,采用倾向性评分匹配模型比较商业保险中COVID-19住院患者(病例组)与未住院COVID-19患者(对照组)的医疗支出趋势。
主要发现
- 基于倾向性评分匹配,住院患者初始COVID-19就诊后30天平均总医疗支出高96%,120天高近70%。
- 30天后平均支出差异为11242美元,120天后为4959美元。
- 支出差异在60天后住院服务和住院入院最高,达56862美元;120天后药品最低,为329美元。
- 合并高血压或糖尿病者总支出差异更大,30天后为14958美元,120天后为5962美元。
临床怎么用
- 全科医生应关注COVID-19住院患者出院后的医疗费用负担,尤其合并高血压或糖尿病者。
- 接种疫苗预防COVID-19住院可减少后续医疗支出,具有经济价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postacute sequelae of coronavirus (PASC) disease of 2019 (COVID-19) include morbidity and mortality, but little is known of the impact on medical expenditures. This study measures patients' health care costs after COVID hospitalization before vaccinations. METHODS: The Merative MarketScan database is used to track trends in medical expenditures for commercially insured patients hospitalized for COVID-19 (case subjects) compared with COVID-19 patients not hospitalized (control subjects) using a propensity score matching model. Medical expenditures were estimated from 30-, 60-, and 120-day clean periods after an initial COVID-19 encounter through the end of 2020. RESULTS: Average total medical expenditures were 96% higher for individuals hospitalized for COVID-19 starting 30 days after initial COVID-19 encounter and almost 70% higher 120 days after based on the propensity score matching. The average spending differential was $11,242 30 days after and $4959 120 days after. This effect is highest for inpatient admissions and services 60 days after at $56,862 and lowest among pharmaceuticals 120 days after at $329. The magnitude of the difference is greater for those with hypertension or diabetes where total expenditures is $14,958 30 days after, and $5962 120 days after compared with those without these chronic conditions. DISCUSSION: The results suggest both health and economic implications for COVID-19 hospitalization and supports the use of vaccinations to help mitigate these implications. PASC includes increased health care costs for hospitalized patients, particularly for those with chronic conditions. Preventing COVID-19 hospitalization has economic value in terms of reduced medical spending in addition to health benefits associated with reduced morbidity and mortality.
引用
- Khan T, Tsipas S, Wozniak GD, et al. Health Care Costs Following COVID-19 Hospitalization Prior to Vaccine Availability. J Am Board Fam Med. 2024. PMID: 37857443. doi:10.3122/jabfm.2023.230069R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。